<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD), one of the most common <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e>, is caused by the disruption of hepatic <z:chebi fb="23" ids="18059">lipid</z:chebi> homeostasis </plain></SENT>
<SENT sid="1" pm="."><plain>It is associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> as seen in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) is an incretin that increases insulin sensitivity and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">aids</z:e> <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
<SENT sid="3" pm="."><plain>In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
<SENT sid="4" pm="."><plain>In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD </plain></SENT>
</text></document>